CB02 / Cartography Biosci - LARVOL DELTA

Preclinical investigation of a novel tumor associated antigen, cb02, as a bispecific t-cell engager in cancer (AACR 2026) - "The associated TCE exhibits high affinity and compelling in vitro and in vivo efficacy across both hematological and solid tumor models. These data strongly support the continued development of this CB02-targeted bispecific TCE antibody for clinical evaluation."

Bispecific • IO biomarker • Preclinical • Oncology • Solid Tumor